Insmed gains on revenue forecasts raise

By Reuters News

** Shares of drugmaker Insmed INSM.O advance 14.7% to $11.39, set for their biggest daily jump in over two months

** Co raises annual revenue forecast to $1.35 bln to $1.40 billion from its lung disease treatment Brinsupri, from $1.25 bln to $1.4 bln

** Also raises expectation of revenue from Arikayce, its drug for Mycobacterium avium complex (MAC) lung disease, to between $460 mln and $470 mln from $450 mln to $470 mln

** Q3 revenue also beat expectations, marking the 10th consecutive quarter of revenue beat, per LSEG-compiled data

** Robust demand for Brinsupri in the US market and Arikayce in international markets support forecast raise - co

** 24 analysts rate stock "buy" or higher, 1 "hold", median PT at $196.50 - LSEG

** Stock still down 36% YTD, including session's move

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.